Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the transaction, the general counsel now directly owns 118,265 shares of the company's stock, valued at approximately $1,808,271.85. This represents a 4.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Centessa Pharmaceuticals Trading Up 2.0 %
Shares of NASDAQ CNTA traded up $0.29 during midday trading on Friday, reaching $15.16. The company had a trading volume of 459,371 shares, compared to its average volume of 531,983. The stock has a market cap of $2.00 billion, a PE ratio of -9.91 and a beta of 1.53. Centessa Pharmaceuticals plc has a one year low of $7.38 and a one year high of $18.97. The firm's fifty day moving average price is $16.90 and its 200-day moving average price is $14.54. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.05. On average, equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on CNTA. B. Riley began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 price objective for the company. TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating for the company. Guggenheim raised their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday, November 15th. Finally, Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $25.83.
View Our Latest Research Report on CNTA
Institutional Investors Weigh In On Centessa Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTA. Mirae Asset Global Investments Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock worth $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after purchasing an additional 865 shares during the period. Atria Investments Inc grew its stake in shares of Centessa Pharmaceuticals by 7.0% in the third quarter. Atria Investments Inc now owns 17,134 shares of the company's stock worth $274,000 after purchasing an additional 1,116 shares during the last quarter. Quarry LP grew its stake in shares of Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company's stock worth $87,000 after purchasing an additional 3,108 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 99.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company's stock valued at $217,000 after purchasing an additional 6,785 shares during the period. 82.01% of the stock is currently owned by institutional investors.
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
